Marasca Claudio, Ruggiero Angelo, Cacciapuoti Sara, Fabbrocini Gabriella, Annunziata Maria C
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy -
Ital J Dermatol Venerol. 2022 Dec;157(6):510-514. doi: 10.23736/S2784-8671.22.07361-3. Epub 2022 Sep 30.
Acne is a chronic inflammatory disease of the pilosebaceous unit resulting from different cofactors. The alteration of the skin microbiome has recently been revealed to play a role in acne pathogenesis. Concerns with side effects of available systemic treatment for acne resulted in a greater focus on topical therapies, such as topical azelaic acid which showed to be an effective and safe treatment option for acne. The aim of our study was to evaluate the efficacy of a new treatment protocol for acne based on an oral supplement composed of biotin and 3 strains of lactic ferments combined with a topical gel composed of azelaic acid, hydroxypinacolone retinoate, and α-hydroxy acids.
An Italian single-center interventional study was performed enrolling patients suffering from mild-to-moderate-acne. Patients were treated with a supplement based on biotin and 3 strains of lactic ferments, combined with a topical gel product (azelaic-acid, hydroxypinacolone retinoate, and α-hydroxy acids). All enrolled patients were scheduled for a total of 2 visits, a baseline visit (V0) and a follow-up visit after 60 days of treatment (V1).
A total of 30 patients were enrolled in the study. Between V0 (baseline) and V1 (60 days), there was a reduction of 37.4% in the GAGS Score, 40.7% in the SEBUTAPEtm Score, and 18% in the TEWL Score, and an increment of 44% in the T-Blue Test Score. No cases of serious AEs were reported in our experience.
Our results confirmed the promising therapeutic role of a probiotic supplement associated with topical therapy in the treatment of mild to moderate acne.
痤疮是一种由多种因素引起的毛囊皮脂腺单位的慢性炎症性疾病。最近发现皮肤微生物群的改变在痤疮发病机制中起作用。由于对现有痤疮全身治疗副作用的担忧，人们更加关注局部治疗，如局部使用壬二酸，它被证明是一种有效且安全的痤疮治疗选择。我们研究的目的是评估一种新的痤疮治疗方案的疗效，该方案基于一种由生物素和3株乳酸发酵菌组成的口服补充剂，联合一种由壬二酸、羟基频哪酮视黄酸酯和α - 羟基酸组成的局部凝胶。
进行了一项意大利单中心干预性研究，纳入轻至中度痤疮患者。患者接受基于生物素和3株乳酸发酵菌的补充剂治疗，并联合一种局部凝胶产品（壬二酸、羟基频哪酮视黄酸酯和α - 羟基酸）。所有纳入患者共安排2次就诊，一次基线就诊（V0）和治疗60天后的随访就诊（V1）。
共有30名患者纳入该研究。在V0（基线）和V1（60天）之间，GAGS评分降低了37.4%，SEBUTAPEtm评分降低了40.7%，经皮水分流失（TEWL）评分降低了18%，T - 蓝试验评分增加了44%。根据我们的经验，未报告严重不良事件病例。
我们的结果证实了益生菌补充剂联合局部治疗在轻至中度痤疮治疗中具有有前景的治疗作用。
